• The importance of detecting group B streptococcus in prenatal screening to prevent the development of early infections in newborns
en To content

The importance of detecting group B streptococcus in prenatal screening to prevent the development of early infections in newborns

HEALTH OF WOMAN. 2019.9(145): 16–22; doi 10.15574/HW.2019.145.16
A.V. Shumytskyi3, O.A. Burka1,3, T.M. Tutchenko2,3
1Bogomolets National Medical University, Kiev
2SI «Institute of pediatrics, obstetrics and ginecology named academic Elena. M. Lukyanova NAMS of Ukraine»
3ML «DILA», Kyiv

Group B streptococcal infection (GBS) remains the most common cause of neonatal early sepsis and an important cause of late onset of sepsis in young children. The use of intrapartum antibiotic prophylaxis is the only currently effective strategy for the prevention of perinatal GBS infection in the early stages of the disease, that is, during the first week of life. GBS causes both early and late infections in newborns, but modern interventions are effective only to prevent diseases at an early stage [1]. The American Academy of Pediatrics teamed up with the American College of Obstetricians and Gynecologists to confirm the use of universal antenatal microbiological testing to detect colonization of GBS in the mother to facilitate the appropriate introduction of intrapartum antibacterial prevention.

All recommendations for the prevention of diseases caused by group B streptococcus proposed by the CDC (Centers for Disease Control and Prevention) refer to the 2010 recommendations. The CDC will support these resources until the American Academy of Pediatrics (AAP), the American College of Obstetricians and Gynecologists (ACOG), and the American Society for Microbiology (ASM) publish all their updated guidelines [2].

Key words: prenatal screening, culture method, group B streptococcus, S.agalactiae, microbiome, colonization.


1. Verani JR, McGee L, Schrag SJ. 2010, Nov 19. Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease–revised guidelines from CDC, 2010. MMWR Recomm Rep. 59 (RR-10):1-36.

2. CDC (Centers for Disease Control and Prevention), https://www.cdc.gov/groupbstrep/guidelines/

3. Ohlsson A, Shah VS. 2013. Intrapartum antibiotics for known maternal Group B streptococcal colonization. Cochrane Database Syst Rev. 1:CD007467. https://doi.org/10.1002/14651858.CD007467.pub3

4. Centers for Disease Control and Prevention. Prevention of perinatal group B streptococcal disease–revised guidelines from CDC, 2010. MMWR Recomm Rep. 59(RR-10):1-36. 2010.

5. Oh W. 2013. Early onset neonatal group B streptococcal sepsis. Am J Perinatol. 30(2):143–147. https://doi.org/10.1055/s-0032-1332804; PMid:23322392

6. Campbell JR, Hillier SL, Krohn MA, Ferrieri P, Zaleznik DF, Baker CJ. 2000. Group B streptococcal colonization and serotype-specific immunity in pregnant women at delivery. Obstet Gynecol 96:498–503. https://doi.org/10.1097/00006250-200010000-00003; PMid:11004347

7. Kwatra G, Cunnington MC, Merrall E, Adrian PV, Ip M, Klugman KP et al. 2016. Prevalence of maternal colonisation with group B streptococcus: a systematic review and meta-analysis. Lancet Infect Dis 16:1076–84. https://doi.org/10.1016/S1473-3099(16)30055-X

8. Phares CR, Lynfield R, Farley MM, Mohle-Boetani J, Harrison LH, Petit S et al. 2008. Epidemiology of invasive group B streptococcal disease in the United States, 1999–2005. Active Bacterial Core surveillance/Emerging Infections Program Network. JAMA 299:2056–65. https://doi.org/10.1001/jama.299.17.2056; PMid:18460666

9. Seale AC, Bianchi-Jassir F, Russell NJ, Kohli-Lynch M, Tann CJ, Hall J et al. 2017. Estimates of the burden of group B streptococcal disease worldwide for pregnant women, stillbirths, and children. Clin Infect Dis 65:S200–19. https://doi.org/10.1093/cid/cix664; PMid:29117332 PMCid:PMC5849940

10. Muller AE, Oostvogel PM, Steegers EA, Dorr PJ. 2006. Morbidity related to maternal group B streptococcal infections. Acta Obstet Gynecol Scand 85:1027–37. https://doi.org/10.1080/00016340600780508; PMid:16929406

11. Regan JA, Klebanoff MA, Nugent RP, Eschenbach DA, Blackwelder WC, Lou Y, Gibbs RS, Rettig PJ, Martin DH, Edelman R. 1996, Apr. Colonization with group B streptococci in pregnancy and adverse outcome. VIP Study Group. Am. J. Obstet. Gynecol. 174(4):1354-60. https://doi.org/10.1016/S0002-9378(96)70684-1

12. Boyer KM, Gotoff SP. 1985. Strategies for chemoprophylaxis of GBS early-onset infections. Antibiot Chemother. 35:267–280. https://doi.org/10.1159/000410380; PMid:3931544

13. Puopolo KM, Baker CJ. Group B streptococcal infections in neonates and young infants. UpToDate. Accessed 2015, January 1.

14. Baker C. Chemoprophylaxis for the prevention of neonatal group B streptococcal disease. http://cursoenarm.net/UPTODATE/contents/mobipreview.htm?21/16/21761?source=HISTORY. Accessed 2015, January 2.

15. Australasian society for infectious diseases. 2014.

16. Vergnano et al. Missed opportunities for preventing GBS infections. 2009. Arch Dis Child Fetal Neonatal Ed.

17. Antibiotic Prevention for Maternal Group B Streptococcal Colonization on Neonatal GBS-Related Adverse Outcomes: A Meta-Analysis, Shunming Li, Jingya Huang. 2017.

18. Early onset Group B Streptococcal disease Queensland clinical guidelines. 2016.

19. Schrag SJ, Verani JR. 2013, Aug 28. Intrapartum antibiotic prophylaxis for the prevention of perinatal group B streptococcal disease: experience in the United States and implications for a potential group B streptococcal vaccine. Vaccine 31;4:D20-6. https://doi.org/10.1016/j.vaccine.2012.11.056; PMid:23219695

20. American College of Obstetricians and Gynecologists Committee on Obstetric Practice. ACOG Committee Opinion 485: Prevention of early-onset group B streptococcal disease in newborns. Obstet Gynecol.  117(4):1019-27. 2011, Apr. https://doi.org/10.1097/AOG.0b013e318219229b; PMid:21422882

21. Group B Streptococcus (GBS) – Prevention of Early – Onset Neonatal Infection. 2017-01-27.

22. Group-b-strep support, http://gbss.org.uk.

23. Virranniemi M, Raudaskoski T, Haapsamo M, Kauppila J, Renko M, Peltola J et al. 2018. The effect of screening-to-labor interval on the sensitivity of late pregnancy culture in the prediction of group B streptococcus colonization at labor: a prospective multicenter cohort study (preprint). Acta Obstet Gynecol Scand.  https://doi.org/10.1111/aogs.13522; PMid:30578547.

24. Nanduri SA, Petit S, Smelser C, Apostol M, Alden NB, Harrison LH et al. 2019. Epidemiology of invasive early-onset and late-onset group B streptococcal disease in the United States, 2006 to 2015: multistate laboratory and population-based surveillance (preprint). JAMA Pediatr. https://doi.org/10.1001/jamapediatrics.2018.4826; PMid:30640366 PMCid:PMC6439883.

25. Puopolo KM, Benitz WE, Zaoutis TE. 2018. Management of neonates born at >/=35 0/7 weeks’ gestation with suspected or proven early-onset bacterial sepsis. Committee on Fetus and Newborn, Committee on Infectious Diseases. Pediatrics 142:e20182894. https://doi.org/10.1542/peds.2018-2894; PMid:30455342

26. Key recommendations from Royal College of Obstetricians & Gynaecologists’ 2017 Prevention of Early-onset Neonatal Group B Streptococcal (GBS) Disease Green-top Guideline 36.

27. Young BC, Dodge LE et al. 2011. Evaluation of a rapid, real-time intrapartum group B streptococcus assay. Am J Obstet Gynecol 205(4): 372 e371-376. https://doi.org/10.1016/j.ajog.2011.06.087; PMid:21864820 PMCid:PMC3217120